Press Releases

Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc.

Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is

Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders Lisata’s Board of Directors and management continues to evaluate strategic alternatives to enhance stockholder value In order to reduce operating expenses and

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones The transaction

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously approved the transaction and recommends that stockholders tender their shares Transaction expected

Lisata regains full development rights to certepetide in the Greater China Region BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of

Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock BASKING RIDGE, N.J., Jan.